Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

被引:9
作者
Balbi, Gustavo G. M. [1 ,2 ]
Ahmadzadeh, Yasaman [3 ]
Tektonidou, Maria G. [4 ]
Pengo, Vittorio [5 ]
Sciascia, Savino [6 ]
Ugarte, Amaia [7 ]
Belmont, H. Michael [8 ]
Lopez-Pedrera, Chary [9 ]
Fortin, Paul R. [10 ]
Wahl, Denis [11 ,12 ,13 ]
Gerosa, Maria [14 ]
de Jesus, Guilherme R. [15 ]
Ji, Lanlan [16 ]
Atsumi, Tatsuya [17 ]
Efthymiou, Maria [18 ]
Branch, D. Ware [19 ,20 ]
Nalli, Cecilia [21 ]
Rodriguez Almaraz, Esther [22 ]
Petri, Michelle [23 ]
Cervera, Ricard [24 ]
Knight, Jason S. [25 ]
Artim-Esen, Bahar [26 ]
Willis, Rohan [27 ]
Bertolaccini, Maria Laura [28 ]
Cohen, Hannah [18 ]
Roubey, Robert [29 ]
Erkan, Doruk [3 ]
Oliveira de Andrade, Danieli Castro [1 ]
机构
[1] Univ Sao Paulo, Sao Paulo, SP, Brazil
[2] Univ Fed Juiz de Fora, Juiz De Fora, MG, Brazil
[3] Weill Cornell Med, Hosp Special Surg, Barbara Volcker Ctr Women & Rheumat Dis, New York, NY USA
[4] Natl & Kapodistrian Univ Athens, Athens, Greece
[5] Univ Hosp Padova, Padua, Italy
[6] Univ Turin, Ctr Res Immunopathol & Rare Dis, Turin, Italy
[7] Hosp Univ Cruces Pais Vasco, Baracaldo, Spain
[8] New York Univ, Hosp Joint Dis, New York, NY USA
[9] Univ Cordoba, Rheumatol Serv, IMIBIC, Reina Sofia Hosp, Cordoba, Spain
[10] Univ Laval, Chu Quebec, Quebec City, PQ, Canada
[11] Univ Lorraine, INSERM, DCAC, Nancy, France
[12] CHRU Nancy, Vasc Med Div, Nancy, France
[13] CHRU Nancy, Reg Competence Ctr Rare Vasc & System Autoimmune, Nancy, France
[14] IRCCS Ist Auxol Italiano, Clin Immunol & Rheumatol Unit, Milan, Italy
[15] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil
[16] Peking Univ First Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
[17] Hokkaido Univ Hosp, Sapporo, Japan
[18] UCL, Haemostasis Res Unit, Dept Haematol, London, England
[19] Univ Utah, Salt Lake City, UT USA
[20] Intermt Healthcare, Salt Lake City, UT USA
[21] ASST Spedali Civili Brescia, Rheumatol & Immunol Unit, Brescia, Italy
[22] Hosp Univ 12 Octubre, Madrid, Spain
[23] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[24] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain
[25] Univ Michigan, Div Rheumatol, Ann Arbor, MI USA
[26] Istanbul Univ, Sch Med, Istanbul, Turkiye
[27] Univ Texas Med Branch, Antiphospholipid Standardizat Lab, Galveston, TX USA
[28] Kings Coll London, British Heart Fdn, Ctr Excellence, Sch Cardiovasc Med & Sci,Acad Dept Vasc Surg, London, England
[29] Univ N Carolina, Chapel Hill, NC USA
关键词
antiphospholipid syndrome; antiphospholipid antibodies; lupus anticoagulant; anticardiolipin; anti-beta-2 glycoprotein I antibodies; damage; cardiovascular disease; risk factors; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ORGAN DAMAGE; INITIAL VALIDATION; AMERICAN-COLLEGE; CLASSIFICATION; PATHOGENESIS; ASSOCIATION; CRITERIA;
D O I
10.1093/rheumatology/kead292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. Methods In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. Results Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), a & beta;(2)GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016). Conclusions DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
引用
收藏
页码:772 / 779
页数:8
相关论文
共 32 条
  • [1] 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022
    American Diabetes Association Professional Practice Committee
    [J]. DIABETES CARE, 2022, 45 : S17 - S38
  • [2] Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)
    Amigo, M-C
    Goycochea-Robles, M. V.
    Espinosa-Cuervo, G.
    Medina, G.
    Barragan-Garfias, J. A.
    Vargas, A.
    Jara, L. Javier
    [J]. LUPUS, 2015, 24 (09) : 927 - 934
  • [3] [Anonymous], 2016, Endocr Pract, V22, P1
  • [4] RISK FOR SUSTAINED AMENORRHEA IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS RECEIVING INTERMITTENT PULSE CYCLOPHOSPHAMIDE THERAPY
    BOUMPAS, DT
    AUSTIN, HA
    VAUGHAN, EM
    YARBORO, CH
    KLIPPEL, JH
    BALOW, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (05) : 366 - 369
  • [5] Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome
    Cervera, R
    Font, J
    Gómez-Puerta, JA
    Espinosa, G
    Cucho, M
    Bucciarelli, S
    Ramos-Casals, M
    Ingelmo, M
    Piette, JC
    Shoenfeld, Y
    Asherson, RA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) : 1205 - 1209
  • [6] Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality
    Dall'Ara, F.
    Reggia, R.
    Taraborelli, M.
    Andreoli, L.
    Taglietti, M.
    Frassi, M.
    Franceschini, F.
    Tincani, A.
    [J]. LUPUS, 2014, 23 (12) : 1255 - 1258
  • [7] The Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
    Duarte-Garcia, Ali
    Pham, Michael M.
    Crowson, Cynthia S.
    Amin, Shreyasee
    Moder, Kevin G.
    Pruthi, Rajiv K.
    Warrington, Kenneth J.
    Matteson, Eric. L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71 (09) : 1545 - 1552
  • [8] Erkan D, 2000, J RHEUMATOL, V27, P2817
  • [9] The Pathogenesis of the Antiphospholipid Syndrome
    Giannakopoulos, Bill
    Krilis, Steven A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (11) : 1033 - 1044
  • [10] The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
    Gladman, D
    Ginzler, E
    Goldsmith, C
    Fortin, P
    Liang, M
    Urowitz, M
    Bacon, P
    Bombardieri, S
    Hanly, J
    Hay, E
    Isenberg, D
    Jones, J
    Kalunian, K
    Maddison, P
    Nived, O
    Petri, M
    Richter, M
    SanchezGuerrero, J
    Snaith, M
    Sturfelt, G
    Symmons, D
    Zoma, A
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (03): : 363 - 369